ONS BIO LLC

CMC Pharmaceuticals, Inc. is a leading pharmaceutical product development company based in Solon, OH. With a team of experienced scientists and subject matter experts, they offer a comprehensive range of services including formulation development, analytical chemistry, stability evaluations, drug delivery system design, and more. Their commitment to timeliness, transparency, and cost-effectiveness sets them apart in the industry. Specializing in innovative complex delivery systems, CMC Pharmaceuticals leverages their expertise in polymeric controlled release, in situ forming gels, suspensions, and more to help clients achieve their drug product development goals. From pre-formulation to commercial scale-up, their laboratory and pilot plant facilities enable them to provide efficient and effective solutions throughout the entire drug development cycle. Complying with cGMP regulations, CMC Pharmaceuticals ensures successful regulatory submissions, clinical trials, and product approval through the FDA.Generated from the website

Strategic Vaccines LLC is a public-private partnership based in Cleveland, Ohio, focused on advancing vaccine development and distribution. The company aims to leverage collaboration between various sectors to enhance public health outcomes. Founded by a coalition of companies, Strategic Vaccines LLC is dedicated to addressing the challenges of vaccine accessibility and innovation. Their mission underscores the importance of strategic alliances in the fight against infectious diseases. Generated from the website

Novel Medical Therapeutics Inc, based in Twinsburg, OH, is pioneering innovative therapies targeting complement-mediated rare diseases, including groundbreaking treatments for conditions such as wet and dry age-related macular degeneration and paroxysmal nocturnal hemoglobinuria. The company is advancing its lead candidates, NM8074 and NM5072, through Phase II clinical trials, demonstrating promising results and a commitment to addressing unmet medical needs. With a robust pipeline of antibody therapies and a unique approach that selectively targets the Alternative Pathway, NovelMed aims to minimize side effects while maintaining the body's defense against infections. The company is actively pursuing partnerships, investments, and acquisition opportunities to further enhance its position in the rare disease market, which is estimated to exceed $400 billion. Generated from the website